Daidzein has neuroprotective effects through ligand-binding-independent PPAR gamma activation

作者:Hurtado O*; Ballesteros I; Cuartero M I; Moraga A; Pradillo J M; Ramirez Franco J; Bartolome Martin D; Pascual D; Torres M; Sanchez Prieto J; Salom J B; Lizasoain I; Moro M A
来源:Neurochemistry International, 2012, 61(1): 119-127.
DOI:10.1016/j.neuint.2012.04.007

摘要

Phytoestrogens are a group of plant-derived compounds that include mainly isoflavones like daidzein. Phytoestrogens prevent neuronal damage and improve outcome in experimental stroke; however, the mechanisms of this neuroprotective action have not been fully elucidated. In this context, it has been postulated that phytoestrogens might activate the peroxisome proliferator-activated receptor-gamma (PPAR gamma), which exerts neuroprotective effects in several settings. The aim of this study was to determine whether the phytoestrogen daidzein elicits beneficial actions in neuronal cells by mechanisms involving activation of PPAR gamma. Our results show that daidzein (0.05-5 mu M) decreases cell death induced by exposure to oxygen-glucose deprivation (OGD) from rat cortical neurons and that improves synaptic function, in terms of increased synaptic vesicle recycling at nerve terminals, being both effects inhibited by the PPAR gamma antagonist T0070907 (1 mu M). In addition, this phytoestrogen activated PPAR gamma in neuronal cultures, as shown by an increase in PPAR gamma transcriptional activity. Interestingly, these effects were not due to binding to the receptor ligand site, as shown by a TR-FRET PPAR gamma competitive binding assay. Conversely, daidzein increased PPAR gamma nuclear protein levels and decreased cytosolic ones, suggesting nuclear translocation. We have used the receptor antagonist (RE) fulvestrant to study the neuroprotective participation of daidzein via estrogen receptor and at least in our model, we have discarded this pathway. These results demonstrate that the phytoestrogen daidzein has cytoprotective properties in neurons, which are due to an increase in PPAR gamma activity not mediated by direct binding to the receptor ligand-binding domain but likely due to post-translational modifications affecting its subcellular location and not depending to the RE and it is not additive with the agonist rosiglitazone.

  • 出版日期2012-7